Glaxosmithkline, LLC

Glaxosmithkline, LLC, doing business as Glaxosmithkline, is a foreign-owned pharmaceutical manufacturer headquartered in Durham, North Carolina that sells vaccines, antiviral medications, and medical countermeasures to federal agencies as a prime contractor exclusively—the vendor holds no subcontract footprint and competes full-and-open across a broad portfolio of 1,628 awards spanning 143 federal customer agencies. Glaxosmithkline does not pursue set-aside categories and operates across civilian and defense agencies without SBA certifications.

Customer concentration centers overwhelmingly on health agencies and the Defense Logistics Agency. The Centers for Disease Control and Prevention (CDC) Pittsburgh dominates by potential value, anchoring 87 awards worth $20.28 billion combined—representing 46% of the vendor's total portfolio value and reflecting GSK's role as a primary vaccine supplier for the CDC's immunization programs including Vaccines for Children (VFC), adult vaccines, and pediatric influenza vaccines. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 ranks second at $11.83 billion across 29 awards, driven by large-ceiling IDV vehicles for influenza and other pharmaceutical products. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) contributes $7.55 billion across 55 awards—notably including major task orders for AS03 adjuvant fill-finish, storage and stability services, and H5 pandemic readiness medical countermeasures. The Defense Logistics Agency Troop Support Medical places the largest award count (495 awards) but carries only $402.9 million combined potential value, reflecting transactional vaccine and antiviral delivery orders. By awards-per-year velocity, GSK logged 127 awards in 2022, 24 in 2023, 113 in 2024, 15 in 2025, and 5 in 2026 to date—signaling uneven ordering patterns consistent with agency-specific procurement cycles and flu season timing.

Parent contract vehicles reflect GSK's dual role as both IDV holder and delivery-order vendor. The Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) anchors 245 task orders worth $40.1 million in combined potential value, with ordering agencies including the Army, FBI, Department of State, and Bureau of Prisons. GSK holds numerous single-award and multiple-award IDVs with the CDC for pediatric and adult vaccines, influenza vaccines, and vaccine storage services, with ceilings ranging from $13.9 million to $1.49 billion. Notable IDVs include a $1.465 billion Vaccines for Children contract (CDC, April 2026–March 2027), a $182.6 million Fluticasone/Salmeterol inhalers vehicle (VA National Acquisition Center, August 2026–July 2027), and a $14 billion-plus storage and stability services contract for AS03 adjuvant and vaccine antigens with ASPR (February 2024–May 2027). Indefinite delivery contracts SPE2DP16D0009, 36E79719D0017, and SPE2DP18D0010 each carry 100+ task orders worth low millions—secondary vehicles for pharmaceutical supply chain support.

Concrete capabilities center on vaccine manufacturing, fill-finish manufacturing, and pharmaceutical supply chain services. Representative examples include a $94.4 million ASPR delivery order (May 2024, H5 pandemic readiness and influenza medical countermeasures) under parent IDIQ 75A50122D00002; a $45.5 million delivery order for RELENZA (zanamivir) supply to ASPR (September 2025–September 2030); a $15.4 million fill-finish order for AS03 adjuvant multi-dose vials supporting COVID-19 response (February 2024, ASPR); a $14 million storage and stability services contract for AS03 adjuvant bulk lots and final containers (February 2024–May 2027, ASPR); $8.8 million zanamivir supply to ASPR (August 2023); and $2.8 million vaccine storage and rotation services to CDC (August 2023–August 2028). Below these anchor awards, GSK fills thousands of smaller delivery orders for flu vaccines, hepatitis vaccines, pneumococcal vaccines, and antiviral medications across Bureau of Prisons facilities, VA networks, and other agencies—typical order values $2,400 to $50,000 for inmate and staff immunization programs.

Eight awards with ultimate completion dates within the next twenty-four months carry combined potential value of $132.8 million and present recompete exposure. The most material near-term risk is on CDC VFC and adult vaccine IDVs expiring through mid-2027 and on ASPR medical countermeasures and adjuvant storage IDIQs reaching completion in early 2027, where renewal competition will determine GSK's continued access to these high-value vehicles.

Activity has been volatile. The vendor transitioned from 127 awards in 2022 to 24 in 2023 (a 81% decline), rebounded to 113 in 2024, then dropped to 15 in 2025 and 5 in 2026 year-to-date. This pattern reflects the episodic nature of vaccine procurement cycles, COVID-19 response wind-down, and the timing of annual CDC and VA solicitations rather than competitive loss. The combined potential value across all 1,628 awards stands at $44.33 billion, with $15.33 billion obligated (35% draw rate), indicating a backlog of unexercised IDV ceiling across mature contracts.

Glaxosmithkline operates exclusively as a prime contractor with zero subcontract footprint—it neither subcontracts to other primes nor receives sub-awards. Capability concentration sits in pharmaceutical preparation manufacturing (1,420 of 1,628 awards by NAICS 325412), biological product manufacturing (68 awards), and medicinal/botanical manufacturing (44 awards). PSC coding aligns tightly: 1,455 awards fall under Drugs and Biologicals, 76 under Medical and Surgical Instruments/Equipment/Supplies, and 27 under Pharmacy Services. The vendor's federal footprint is pure pharmaceutical supply—no IT, consulting, logistics, or professional services revenue.